Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles

AAPS PharmSciTech

Volumn 16, Issue 5, 2015, Pages 1108-1121

  Sharma, Deepak ^a   Sharma, Rakesh Kumar ^b   Sharma, Navneet ^b   Gabrani, Reema ^a   Sharma, Sanjeev K ^a   Ali, Javed ^c   Dang, Shweta ^a  

^a JAYPEE INSTITUTE OF INFORMATION TECHNOLOGY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

controlled release; nanoparticles; process optimization; scintigraphy

Indexed keywords

DIAZEPAM; NANOPARTICLE; POLYGLACTIN; POLYMER; SURFACTANT; TECHNETIUM 99M; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD; BRAIN; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; EX VIVO STUDY; GAMMA SCINTIGRAPHY; INFRARED SPECTROSCOPY; MTT ASSAY; NONHUMAN; NOSE MUCOSA; PRECIPITATION; PRIORITY JOURNAL; RAT; SHEEP; SUSPENSION; VERO CELL LINE; ZETA POTENTIAL; ANIMAL; CELL SURVIVAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; DIAGNOSTIC IMAGING; DRUG ABSORPTION; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; MALE; METABOLISM; NANOTECHNOLOGY; PARTICLE SIZE; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; CALORIMETRY, DIFFERENTIAL SCANNING; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CHEMICAL PRECIPITATION; DIAZEPAM; DRUG CARRIERS; DRUG COMPOUNDING; LACTIC ACID; MALE; NANOPARTICLES; NANOTECHNOLOGY; NASAL ABSORPTION; NASAL MUCOSA; PARTICLE SIZE; POLYGLYCOLIC ACID; RADIOPHARMACEUTICALS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE-ACTIVE AGENTS; TISSUE DISTRIBUTION; VERO CELLS;

EID: 84944511841     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0294-0     Document Type: Article

References (55)

1. Shorvon S, Perucca E, Engel Jr J. The treatment of epilepsy. 3rd ed. UK: Wiley-Blackwell West Sussex; 2009.
2. Henney 3rd HR, Sperling MR, Rabinowicz AL, Bream G, Carrazana EJ. Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults. Epilepsy Res. 2014;108:1204–11.
3. Ivaturi VD, Riss JR, Kriel RL, Cloyd JC. Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. Acta Neurol Scand. 2009;120:353–7.
4. Sperling MR, Haas KF, Krauss G, Seif Eddeine H, Henney 3rd HR, Rabinowicz AL, et al. Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy. Epilepsia. 2014;55:1544–50.
5. Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014;5:709–33.
6. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:18. doi:10.1155/2013/238428.
7. Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9:566–82.
8. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481–96.
9. Westin UE, Boström E, Gråsjö J, Hammarlund-Udenaes M, Björk E. Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm Res. 2006;23:565–72.
10. Shingaki T, Hidalgo IJ, Furubayashi T, Katsumi H, Sakane T, Yamamoto A, et al. The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid). Int J Pharm. 2009;377:85–91.
11. Patil SB, Sawant KK. Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery. J Microencapsul. 2009;26:432–43.
12. Reis CP, Neufeld RJ, Ribeiro ANJ, Veiga F. Nanoencapsulation I. methods for preparation of drug-loaded polymeric NP. Nanomedicine Nanotech Biol Med. 2006;2:8–21.
13. Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505–22.
14. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010;75:1–18.
15. Lu JM, Wang X, Muller CM, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA based Nanotechnology. Expert Rev Mol Diagn. 2009;9:325–41.
16. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377–97.
17. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine Nanotech Biol Med. 2009;5:369–77.
18. Feczko T, Toth J, Dosa G, Gyenis J. Influence of process conditions on the mean size of PLGA nanoparticles. Chem Eng Process. 2011;50:846–53.
19. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290:7–144.
20. Sharma D, Maheshwari D, Philip G, Rana R, Bhatia S, Singh M, et al. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design: in vitro and in vivo evaluation. Biomed Res Int. 2014. doi:10.1155/2014/156010.
21. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336:367–75.
22. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 2008;69:445–53.
23. Songa KC, Lee HS, Chounga IY, Choa KI, Ahnb Y, Choi EJ. The effect of type of organic phase solvents on the particle size of poly(d, l-lactide-co-glycolide) nanoparticles. Colloids Surf A. 2006;276:162–7.
24. Hao J, Fang X, Wang J, Guo F, Li F, Peng X. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011;6:683–92.
25. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7:4169–76.
26. Fessi et al. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US Patent 1992; 5,118,528.
27. Bilati U, Emann EA, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24:67–75.
28. Hornig S, Heinze T, Becer CR, Schubertb US. Nanoprecipitation and nanoformulation of polymers: from history to powerful possibilities beyond poly(lactic acid). Soft Matter. 2011;7:1581–8.
29. USP30-NF25, Diazepam, 1912.
30. Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Jan V, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine Nanotech Biol Med. 2010;6:662–71.
31. El-Ansary A, Al-Daihan S. On the toxicity of therapeutically used nanoparticles: an overview. J Toxicol 2009; 754810. doi:10.1155/2009/754810.
32. Lei R, Wu C, Yang B, Ma H, Shi C, Wang Q, et al. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. Toxicol Appl Pharmacol. 2008;232:292–301.
33. Campos EVR, Melo NFSD, Guilherme VA, Paula ED, Rosa AH, ArauJo DRD, et al. Preparation and characterization of poly(ε-Caprolactone) nanospheres containing the local anesthetic lidocaine. J Pharm Sci. 2013;102:215–26.
34. Mathew A, Takahiro F, Yutaka N, Takashi H, Hisao M, Yasuhiko Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS ONE. 2012;12(7):e32616.
35. Snehalatha M, Kolachina V, Saha RN, Babbar AK, Sharma N, Sharma RK. Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton’s lymphoma tumor bearing mice. J Pharm Bioallied Sci. 2013;5:38–45.
36. Vyas TK, Babbar AK, Sharma RK, Misra A. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J Drug Target. 2005;13:317–24.
37. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358:285–91.
38. Kumar M, Misra A, Mishra AK, Mishra P, Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target. 2008;16:806–14.
39. Alam S, Khan ZI, Mustafa G, Kumar M, Islam F, Bhatnagar A, et al. Development and evaluation of thymoquinone- encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine. 2012;7:5705–18.
40. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci. 2004;93:1804–14.
41. Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9:1–4.
42. Averineni RK, Shavi GV, Gurram AK, Deshpande PB, Arumugam K, Maliyakkal N, et al. PLGA 50:50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. Bull Mater Sci. 2012;35:319–26.
43. Nah JW, Y-Il J, Koh JJ. Drug release from nanoparticles of poly(dl-lactide-co-glycolide). Korean J Chem Eng. 2006;17:230–6.
44. Ivaturi V, Kriel R, Brundage R, Gordon L, Mansbach H, Cloyd J. Bioavailability of intranasal vs. rectal diazepam. Epilepsy Res. 2013;103:254–61.
45. Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105:362–7.
46. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2007;2:219–32.
47. Sharma D, Gabrani R, Sharma SK, Ali J, Dang S. Development of midazolam loaded PLGA nanoparticles for treatment of status epilepticus. Adv Sci Lett. 2014;20:1526–30.
48. Prajapati RK, Mahajan HS, Surana SJ. PLGA based mucoadhesive microspheres for nasal delivery: in vitro/ex vivo studies. Indian J Novel Drug Deliv. 2011;3:9–16.
49. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24:1113–28.
50. Sylaja B, Srinivasan S. Experimental and theoretical investigation of spectroscopic properties of diazepam. Int J Chem Tech Res. 2012;4:361–76.
51. Mainardes RM, Gremiao MPD, Evangelista RC. Thermoanalytical study of praziquantel-loaded PLGA nanoparticles. Braz J Pharm Sci. 2006;42:523–30.
52. van Woensel M, Wauthoz N, Rosière R, Amighi K, Mathieu V, Lefranc F, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers. 2013;5:1020–48.
53. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29:3867–76.
54. Sharma G, Mishra AK, Mishra P, Misra A. Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies. AAPS PharmSciTech. 2009;10:1321–30.
55. Babu RJ, Dayal PP, Pawar K, Singh M. Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target. 2011;19:731–40.